Vimarsana
Biggest News Aggregation in the World

Page 7 - Genentech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genentech Today - Breaking & Trending Today

How Monica Took an Active Role in Her Breast Cancer Treatment Journey - Vimarsana News

How Monica Took an Active Role in Her Breast Cancer Treatment Journey

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem - Vimarsana News

BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support...

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024 - Vimarsana News

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Vir Biotechnology, Inc. announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer , effective June 03, 2024. Dr. Eisner will be a part of...

Inavolisib Plus Palbociclib/Fulvestrant Earns FDA Priority Review for Advanced HR+/HER2–, PIK3CA+ Breast Cancer - Vimarsana News

Inavolisib Plus Palbociclib/Fulvestrant Earns FDA Priority Review for Advanced HR+/HER2–, PIK3CA+ Breast Cancer

The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.

New treatment regimens improve outlook for patients with HER2-positive breast cancer - Vimarsana News

New treatment regimens improve outlook for patients with HER2-positive breast cancer

Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.

Source: healio.com